Search results
Results From The WOW.Com Content Network
Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells. [ 4 ] [ 5 ] Both autosomal dominant and recessive inheritance have been observed with the disorder; classically, and more commonly, the inheritance is autosomal recessive .
Pyruvate kinase deficiency is the second most common cause of enzyme-deficient hemolytic anemia, following G6PD deficiency. [13] The symptoms of pyruvate kinase deficiency are mild to severe hemolytic Anemia, cholecystolithiasis, tachycardia, hemochromatosis, icteric sclera, splenomegaly, leg ulcers, jaundice, fatigue, and shortness of breath. [14]
Pyruvate kinase is the enzyme involved in the last step of glycolysis. ... The low activity dimer allows for build-up of phosphoenol pyruvate (PEP), ...
anaplerotic therapy, low-fat diet Pyruvate carboxylase deficiency is an inherited disorder that causes lactic acid to accumulate in the blood . [ 2 ] High levels of these substances can damage the body's organs and tissues, particularly in the nervous system.
Based on symptoms, blood test, genetic testing [2] Differential diagnosis: Pyruvate kinase deficiency, hereditary spherocytosis, sickle cell anemia [2] Treatment: Avoiding triggers, medications for infection, stopping offending medication, blood transfusions [3] Frequency: 400 million [1] Deaths: 33,000 (2015) [4]
Common signs and symptoms include poor growth, normal lactate/pyruvate ratio (however both lactate and pyruvate are in higher than normal concentrations), hepatomegaly, lactic acidosis, hypoglycemia, neurological problems, and hypotonia. [6] A disease with comparable symptoms is also seen in autosomal recessive mutations of the MPC2 gene. [7]
Pyruvate dehydrogenase deficiency (also known as pyruvate dehydrogenase complex deficiency or PDCD or PDH deficiency) is a rare neurodegenerative disorder associated with abnormal mitochondrial metabolism. PDCD is a genetic disease resulting from mutations in one of the components of the pyruvate dehydrogenase complex (PDC). [1]
The FDA approved mitapivat based on evidence from two clinical trials of 107 participants with pyruvate kinase deficiency. [3] Trial 1 (NCT03548220) of 80 adults with pyruvate kinase deficiency who did not receive regular blood transfusions and trial 2 (NCT03559699) of 27 adults with pyruvate kinase deficiency who received regular blood transfusions. [3]